Interleukin-21 in cancer immunotherapy: Friend or foe?

Interleukin (IL)-21, a cytokine produced by activated conventional CD4+ T lymphocytes and Natural Killer T cells, drives anti-tumor immunity in the skin and kidney. However IL-21 is also pro-inflammatory in many tissues and promotes colitis-associated colon cancer. Understanding the biology of IL-21...

Descripción completa

Detalles Bibliográficos
Autores principales: Stolfi, Carmine, Pallone, Francesco, MacDonald, Thomas T., Monteleone, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Point of View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382872/
https://www.ncbi.nlm.nih.gov/pubmed/22737612
http://dx.doi.org/10.4161/onci.19122
Descripción
Sumario:Interleukin (IL)-21, a cytokine produced by activated conventional CD4+ T lymphocytes and Natural Killer T cells, drives anti-tumor immunity in the skin and kidney. However IL-21 is also pro-inflammatory in many tissues and promotes colitis-associated colon cancer. Understanding the biology of IL-21 in these different situations is needed to ensure maximal therapeutic benefit.

Ejemplares similares